 Michelle Fullard
Concepts (90)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 15 | 2023 | 323 | 4.140 |
Why?
| | Olfaction Disorders | 4 | 2021 | 50 | 1.370 |
Why?
| | Cognitive Dysfunction | 5 | 2021 | 273 | 1.180 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2020 | 109 | 0.610 |
Why?
| | Patient Readmission | 2 | 2020 | 608 | 0.590 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2020 | 246 | 0.530 |
Why?
| | Disabled Persons | 1 | 2017 | 132 | 0.520 |
Why?
| | Vitamin D Deficiency | 1 | 2017 | 158 | 0.510 |
Why?
| | Length of Stay | 1 | 2020 | 949 | 0.500 |
Why?
| | Physical Therapy Modalities | 1 | 2017 | 264 | 0.470 |
Why?
| | Vitamin D | 1 | 2017 | 341 | 0.460 |
Why?
| | Patient Discharge | 1 | 2020 | 769 | 0.450 |
Why?
| | Healthcare Disparities | 2 | 2019 | 479 | 0.430 |
Why?
| | Sex Characteristics | 1 | 2017 | 635 | 0.430 |
Why?
| | Medicare | 4 | 2019 | 665 | 0.420 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 679 | 0.400 |
Why?
| | Dementia | 2 | 2023 | 186 | 0.300 |
Why?
| | Aged | 12 | 2021 | 19079 | 0.290 |
Why?
| | Alzheimer Disease | 2 | 2023 | 436 | 0.280 |
Why?
| | Aged, 80 and over | 6 | 2020 | 6346 | 0.270 |
Why?
| | Lewy Body Disease | 1 | 2023 | 16 | 0.210 |
Why?
| | United States | 5 | 2019 | 12176 | 0.170 |
Why?
| | Male | 12 | 2020 | 55558 | 0.170 |
Why?
| | Cholinesterase Inhibitors | 1 | 2019 | 23 | 0.160 |
Why?
| | Middle Aged | 8 | 2020 | 26746 | 0.160 |
Why?
| | Female | 11 | 2020 | 59486 | 0.160 |
Why?
| | Elective Surgical Procedures | 1 | 2020 | 151 | 0.160 |
Why?
| | Deep Brain Stimulation | 1 | 2019 | 71 | 0.160 |
Why?
| | Cholinergic Antagonists | 1 | 2019 | 27 | 0.160 |
Why?
| | Cohort Studies | 3 | 2017 | 4899 | 0.160 |
Why?
| | Leukoencephalopathies | 1 | 2018 | 21 | 0.160 |
Why?
| | Humans | 16 | 2023 | 114716 | 0.160 |
Why?
| | Databases, Factual | 2 | 2020 | 1126 | 0.150 |
Why?
| | Disease Progression | 4 | 2019 | 2384 | 0.150 |
Why?
| | Medication Errors | 1 | 2019 | 89 | 0.150 |
Why?
| | Geography, Medical | 1 | 2017 | 10 | 0.150 |
Why?
| | Biomarkers | 2 | 2019 | 3414 | 0.150 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2017 | 40 | 0.140 |
Why?
| | White Matter | 1 | 2018 | 102 | 0.140 |
Why?
| | Proportional Hazards Models | 2 | 2019 | 1080 | 0.140 |
Why?
| | Drug Prescriptions | 1 | 2019 | 239 | 0.140 |
Why?
| | REM Sleep Behavior Disorder | 1 | 2016 | 9 | 0.130 |
Why?
| | Longitudinal Studies | 3 | 2019 | 2382 | 0.130 |
Why?
| | Diagnosis, Differential | 2 | 2017 | 1340 | 0.130 |
Why?
| | tau Proteins | 1 | 2016 | 68 | 0.130 |
Why?
| | Neuropsychological Tests | 2 | 2018 | 913 | 0.130 |
Why?
| | Risk | 1 | 2017 | 815 | 0.120 |
Why?
| | Cognition Disorders | 1 | 2018 | 476 | 0.120 |
Why?
| | Salivary Ducts | 1 | 2013 | 4 | 0.110 |
Why?
| | Myelitis, Transverse | 1 | 2013 | 3 | 0.110 |
Why?
| | Carcinoma, Ductal | 1 | 2013 | 11 | 0.110 |
Why?
| | Parotid Neoplasms | 1 | 2013 | 14 | 0.110 |
Why?
| | Proteomics | 1 | 2019 | 843 | 0.110 |
Why?
| | Spinal Cord Neoplasms | 1 | 2013 | 37 | 0.110 |
Why?
| | Amyloid beta-Peptides | 1 | 2016 | 189 | 0.110 |
Why?
| | Logistic Models | 1 | 2017 | 1843 | 0.100 |
Why?
| | Prevalence | 1 | 2017 | 2249 | 0.100 |
Why?
| | Cognition | 1 | 2018 | 983 | 0.100 |
Why?
| | Incidence | 1 | 2017 | 2312 | 0.100 |
Why?
| | Prognosis | 1 | 2017 | 3334 | 0.080 |
Why?
| | Exercise | 1 | 2018 | 1643 | 0.070 |
Why?
| | Brain | 1 | 2018 | 2369 | 0.070 |
Why?
| | Adult | 3 | 2020 | 30543 | 0.050 |
Why?
| | Retrospective Studies | 1 | 2020 | 12513 | 0.050 |
Why?
| | Smell | 1 | 2021 | 112 | 0.040 |
Why?
| | Osteopontin | 1 | 2019 | 32 | 0.040 |
Why?
| | Amidohydrolases | 1 | 2019 | 28 | 0.040 |
Why?
| | Drug Incompatibility | 1 | 2019 | 1 | 0.040 |
Why?
| | Proteoglycans | 1 | 2019 | 107 | 0.040 |
Why?
| | Extracellular Matrix Proteins | 1 | 2019 | 126 | 0.040 |
Why?
| | Social Class | 1 | 2019 | 204 | 0.040 |
Why?
| | Neurodegenerative Diseases | 1 | 2019 | 91 | 0.040 |
Why?
| | Acute Disease | 1 | 2019 | 912 | 0.030 |
Why?
| | Risk Factors | 2 | 2019 | 8626 | 0.030 |
Why?
| | Resistance Training | 1 | 2018 | 113 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2019 | 696 | 0.030 |
Why?
| | Life Style | 1 | 2018 | 430 | 0.030 |
Why?
| | Internationality | 1 | 2016 | 144 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1449 | 0.030 |
Why?
| | Self Report | 1 | 2018 | 695 | 0.030 |
Why?
| | Thoracic Vertebrae | 1 | 2013 | 68 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2013 | 284 | 0.030 |
Why?
| | Syndrome | 1 | 2013 | 334 | 0.030 |
Why?
| | Algorithms | 1 | 2019 | 1468 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2019 | 2762 | 0.030 |
Why?
| | Radiography | 1 | 2013 | 811 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 4406 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3031 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 4420 | 0.020 |
Why?
| | Prospective Studies | 1 | 2016 | 6216 | 0.010 |
Why?
|
|
Fullard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|